“Preventive medicine” has lately become a hot topic. The safety and efficacy of vaccines and the impacts of “ultra-processed” foods on health have been prominent. One issue related to the prevention of illness that has been largely ignored, yet is increasingly important as the U.S. population ages, is the inadvertent overdosage with common drugs in the elderly, who often require lower doses. Greater awareness by both clinicians and patients could reduce the morbidity and mortality from overdosage.
I was reminded of the issue recently when a physician colleague of mine treated an elderly man who presented with signs and symptoms of a bleeding gastric ulcer – abdominal pain, black, tarry stools, and anemia. The cause was too high a dose of one of the most common over-the-counter pain relievers – ibuprofen (brand names: Advil, Motrin). The patient had been taking the drug at approximately the same dosage intermittently for decades without a problem, but what he didn’t know was that a lower dose would have been more appropriate at his current age (mid 70s).
Aging alters drug metabolism and effects
There is a large body of evidence showing that for many medicines, lower starting or maintenance doses are appropriate for older adults because aging alters drug metabolism (pharmacokinetics) and drug effects (pharmacodynamics). Studies of geriatric pharmacology consistently show reduced renal and hepatic clearance of drugs, higher body fat/less total body water (changing the ratio of distribution of drugs in the body), and increased receptor-level sensitivity for several drug classes. Together, these make standard adult doses more likely to cause toxicity in older adults. And because kidney function commonly declines with age, many drugs cleared by the kidneys require dose reduction keyed to creatinine clearance, a measure of kidney function
The FDA is acutely aware of this phenomenon. In 2024, the Agency published guidance to assist developers of new drugs “planning to conduct studies to assess the influence of renal impairment on the pharmacokinetics of an investigational drug.” It provides recommendations on when and how to conduct such studies.
These are several of the best-studied examples:
Drug classes with direct evidence for lower dosing
Anticoagulants (“blood thinners”)
Over-anticoagulation causes excessive bleeding, the signs of which include:
- Easy bruising or unusually large or spontaneous bruises
- Prolonged bleeding from cuts, nosebleeds, or bleeding gums
- Heavier or prolonged menstrual bleeding
- Bleeding under the skin causing purple or red spots (petechiae or purpura)
- Blood in urine or dark/tarry stools indicating gastrointestinal bleeding
- Vomiting blood or material that looks like coffee grounds
- Coughing up blood
Warfarin (brand name, Coumadin): Multiple cohort analyses show a stepwise decline in maintenance dose with age, even after accounting for genetics and comorbidities – approximately 20%-25% lower from “young” to “elderly” groups. The authors of a large study concluded that warfarin dose requirements decline significantly with age, with older women requiring the lowest dose. They found that “the practice of starting warfarin therapy at 5 mg per day would result in over-anticoagulating a significant number of older patients and recommended lower initiation and maintenance doses in this age group.”
Apixaban (Eliquis): The FDA-approved label calls for a reduced dose (2.5 mg twice a day) when two or more of these conditions are present: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL; this was embedded in the landmark ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) program to preserve safety and efficacy in older subgroups.
Sedatives/sleeping pills
Zolpidem (brand name, Ambien): After pharmacokinetics and pharmacodynamics data showed higher next-morning impairment (especially with slower clearance) at usual doses, the FDA mandated lower recommended doses. Clinicians and patients are advised to use the lowest effective dose in older adults.
Benzodiazepines generally: Classic pharmacokinetics and pharmacodynamics studies show markedly prolonged half-lives (e.g., diazepam) and greater pharmacodynamic sensitivity (e.g., triazolam), which increase the risk of falling and cognitive impairment at “usual” doses. One clinical study recommended that, on average, the starting dose of triazolam should be reduced by 50 percent.
Cardiac drug
Digoxin (Lanoxin): Aging and reduced kidney function reduce clearance from the blood and narrow the safety margin of this important but potentially highly toxic drug. Observational studies and controlled trials link lower serum levels to better outcomes, lending support to trying lower doses in older patients.
Antidepressants
Citalopram (Celexa): FDA has warned of dose-dependent electrocardiogram QT prolongation — a warning sign that the heart’s electrical system is unstable and may be susceptible to a dangerous arrhythmia. Therefore, the maximum dose for patients older than 60 is capped at 20 mg/day.
Evidence-informed rules of thumb
- “Start low, go slow.” Geriatric pharmacology texts and recent systematic reviews (e.g., on dosing of oncology drugs) warn that in many older adults, lower starting doses with cautious titration reduce toxicity without sacrificing effectiveness.
- Use geriatric prescribing tools. A particularly valuable resource is the American Geriatrics Society’s Beers Criteria® for potentially inappropriate medication use in older adults, a comprehensive list of medications that may be dangerous in older people. Such resources flag medicines that need avoidance, dose reduction, or extra monitoring in people older than 65.
Key Takeaways & Recommendations
- While many drugs are lifesaving or improve the quality of life, they can also be harmful, especially in vulnerable populations. Not every medicine needs to be lowered just because the patient is older — but many do, and there are solid data to prove it.
- The best evidence for dosing reductions in older adults exists for anticoagulants (warfarin and similar drugs), sedative-hypnotics/benzodiazepines, digoxin, and certain antidepressants.
- In practice, dosage decisions should be individualized according to kidney function, liver function, body composition, drug interactions, and frailty, generally adopting a “start low, go slow” titration approach. Use the lowest effective dose for the shortest necessary duration, and closely monitor older adults.